8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
May 4, 2026·SEC
Material company update
Mar 24, 2026·SEC
Rezolute, Inc.(RZLT)Earnings, Financials & Key Ratios
RZLT•NASDAQ
Price updated Jun 19, 2026
AboutRezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.Show more
- Revenue$0
- EBITDA-$80M-13.5%
- Net Income-$74M-8.7%
- EPS (Diluted)-0.98+26.3%
- ROE-52.56%+8.9%
RZLT Key Insights
Rezolute, Inc. (RZLT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 94 (top 6%)
✗Weaknesses
- ✗Profits declining 29.6% over 5 years
- ✗Shares diluted 47.7% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when RZLT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RZLT Price & Volume
Rezolute, Inc. (RZLT) stock price & volume — 10-year historical chart
Loading chart...
RZLT Growth Metrics
Rezolute, Inc. (RZLT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-11.63%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM29.31%
Return on Capital
10 Years-4273.62%
5 Years-58.85%
3 Years-51.91%
Last Year-55.73%
RZLT Recent Earnings
Rezolute, Inc. (RZLT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.16-12.3%
$0.14
Rev
—
—
Q1 2026
Feb 12, 2026Metric
Actual
Est
EPS
$0.22-37.5%
$0.16
Rev
—
—
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.18+33.3%
$0.27
Rev
—
—
Q4 2025
Sep 17, 2025Metric
Actual
Est
EPS
$0.26-13.0%
$0.23
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.16vs $0.14-12.3% | — |
| Q1 2026 | Feb 12, 2026 | $0.22vs $0.16-37.5% | — |
| Q4 2025 | Nov 6, 2025 | $0.18vs $0.27+33.3% | — |
| Q4 2025 | Sep 17, 2025 | $0.26vs $0.23-13.0% | — |
Based on last 12 quarters of dataView full earnings history →
RZLT Peer Comparison
Rezolute, Inc. (RZLT) competitors in Metabolic and Obesity Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 XOMA | 525.34M | 41.89 | 28.69 | 83.06% | 86.97% | 30.21% | 1.27 | |
 CGEM | 923.71M | 15.03 | -4.04 | -51.45% | 0.01 | |||
 RARE | 2.7B | 27.44 | -4.71 | 20.13% | -91.03% | -6.08% | ||
 VNDA | 342.83M | 5.80 | -1.55 | 8.72% | -109.99% | -61.41% | 0.04 | |
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 PTCT | 6.55B | 78.98 | 10.15 | 114.51% | -22.58% | |||
 LLY | 1.04T | 1098.13 | 47.85 | 44.7% | 34.98% | 101.17% | 1.60 |
Compare RZLT vs Peers
Rezolute, Inc. (RZLT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RZLT Income Statement
Rezolute, Inc. (RZLT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 12.57M | 1.07M | 48K | 18K | 13K | 0 | 0 | 0 | 0 | 23K |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | -12.57M▲ 0% | -1.07M▲ 91.5% | -48K▲ 95.5% | -18K▲ 62.5% | -13K▲ 27.8% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -23K▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | -52.06% | 91.52% | 95.5% | 62.5% | 27.78% | 100% | - | - | - | - |
Operating Expenses | 20.32M | 26.38M | 25.9M | 20.5M | 22.88M | 41.84M | 55.99M | 70.42M | 79.89M | 87.23M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 8.23M | 9.1M | 6.82M | 6.07M | 7.91M | 9.36M | 12.18M | 14.68M | 18.37M | 27.59M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
Research & Development | 12.09M | 17.28M | 19.08M | 14.45M | 14.99M | 32.49M | 43.81M | 55.74M | 61.53M | 59.77M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 37.14K | 136.13K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -120K |
Operating Income | -20.32M▲ 0% | -28.73M▼ 41.4% | -25.94M▲ 9.7% | -20.52M▲ 20.9% | -22.89M▼ 11.6% | -41.84M▼ 82.8% | -55.99M▼ 33.8% | -70.42M▼ 25.8% | -79.89M▼ 13.4% | -87.25M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | - | - |
Operating Income Growth % | -35.94% | -41.38% | 9.71% | 20.9% | -11.56% | -82.77% | -33.81% | -25.78% | -13.45% | - |
EBITDA | -19.21M | -27.67M | -25.9M | -20.5M | -22.88M | -41.83M | -55.96M | -70.39M | -79.86M | -87.22M |
EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
EBITDA Growth % | -35.28% | -44.03% | 6.41% | 20.83% | -11.6% | -82.82% | -33.78% | -25.78% | -13.46% | -13.11% |
D&A (Non-Cash Add-back) | 1.11M | 1.07M | 48K | 18K | 13K | 13K | 30K | 36K | 31K | 31K |
EBIT | -20.28M | -29.17M | -25.49M | -20.33M | -20.53M | -39.25M | -55.99M | -70.42M | -79.89M | -85.59M |
Net Interest Income | 0 | -688.19K | -4.9M | 188K | -312K | -1.73M | 4.21M | 4.87M | 5.48M | 5.77M |
Interest Income | 0 | 1K | 61K | 188K | 63K | 80K | 4.21M | 4.87M | 5.48M | 5.77M |
Interest Expense | 1.59K | 689.19K | 4.96M | 0 | 375K | 1.81M | 0 | 0 | 0 | 0 |
Other Income/Expense | 46.92K | -1.13M | -4.5M | 188K | 1.99M | 783K | 4.2M | 1.96M | 5.48M | 5.77M |
Pretax Income | -20.28M▲ 0% | -29.86M▼ 47.3% | -30.45M▼ 2.0% | -20.33M▲ 33.2% | -20.9M▼ 2.8% | -41.06M▼ 96.4% | -51.79M▼ 26.1% | -68.46M▼ 32.2% | -74.41M▼ 8.7% | -81.48M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
Income Tax | -11.37K | 0 | -29K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0.06% | 0% | 0.1% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -20.28M▲ 0% | -29.86M▼ 47.3% | -30.42M▼ 1.9% | -20.33M▲ 33.2% | -20.9M▼ 2.8% | -41.06M▼ 96.4% | -51.79M▼ 26.1% | -68.46M▼ 32.2% | -74.41M▼ 8.7% | -81.48M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | - | - |
Net Income Growth % | -35.76% | -47.27% | -1.86% | 33.15% | -2.8% | -96.44% | -26.13% | -32.19% | -8.7% | -11.63% |
Net Income (Continuing) | -20.28M | -29.86M | -30.45M | -20.33M | -20.9M | -41.06M | -51.79M | -68.46M | -74.41M | -81.48M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -24.55▲ 0% | -26.83▼ 9.3% | -17.11▲ 36.2% | -3.54▲ 79.3% | -2.72▲ 23.2% | -2.32▲ 14.7% | -1.01▲ 56.5% | -1.33▼ 31.7% | -0.98▲ 26.3% | -0.78▲ 0% |
EPS Growth % | 18.55% | -9.29% | 36.23% | 79.31% | 23.16% | 14.71% | 56.47% | -31.68% | 26.32% | 29.31% |
EPS (Basic) | -24.55 | -26.83 | -17.11 | -3.54 | -2.72 | -2.26 | -1.01 | -1.33 | -0.98 | - |
Diluted Shares Outstanding | 825.93K | 1.11M | 1.78M | 5.75M | 7.67M | 19.49M | 51.19M | 51.47M | 76M | 104.04M |
Basic Shares Outstanding | 825.93K | 1.11M | 1.78M | 5.75M | 7.67M | 18.2M | 51.19M | 51.47M | 76M | 104.04M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
RZLT Balance Sheet
Rezolute, Inc. (RZLT) balance sheet — assets, liabilities & shareholders' equity
| Metric | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 4.93M | 2.01M | 12.14M | 10.52M | 41.99M | 152.1M | 104.91M | 128.65M | 171.15M | 122.05M |
Cash & Short-Term Investments | 4.49M | 1.65M | 11.57M | 9.96M | 41.05M | 150.41M | 101.9M | 126.87M | 167.86M | 120.27M |
Cash Only | 4.49M | 1.65M | 11.57M | 9.96M | 41.05M | 150.41M | 16.04M | 70.4M | 94.11M | 11.24M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 85.86M | 56.48M | 73.75M | 109.03M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 600K |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 442.01K | 361.92K | 571K | 0 | 0 | 0 | 0 | 1.78M | 3.29M | 1.18M |
Total Non-Current Assets | 5.7M | 495.1K | 108K | 447K | 616K | 316K | 18.81M | 4.08M | 4.34M | 3.41M |
Property, Plant & Equipment | 5.33M | 368.37K | 44K | 416K | 425K | 168K | 2.19M | 1.98M | 1.42M | 967K |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 44.32K | 37.03K | 29K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 16.47M | 263K | 0 | 0 |
Other Non-Current Assets | 330.63K | 89.69K | 35K | 31K | 191K | 148K | 148K | 1.84M | 2.92M | 2.44M |
Total Assets | 10.63M▲ 0% | 2.5M▼ 76.5% | 12.25M▲ 389.5% | 10.96M▼ 10.5% | 42.61M▲ 288.6% | 152.42M▲ 257.7% | 123.72M▼ 18.8% | 132.74M▲ 7.3% | 175.49M▲ 32.2% | 125.46M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | -2.52% | -76.45% | 389.52% | -10.5% | 288.59% | 257.72% | -18.83% | 7.29% | 32.21% | 116.97% |
Total Current Liabilities | 1.77M | 6.25M | 8.38M | 3.23M | 1.97M | 2.46M | 5.2M | 9.61M | 11.91M | 7.7M |
Accounts Payable | 926.04K | 1.71M | 563K | 893K | 1.03M | 1.13M | 3.27M | 4.9M | 5.81M | 3.19M |
Days Payables Outstanding | 26.89 | 584.34 | 4.28K | 18.11K | 29.06K | - | - | - | - | 63.66K |
Short-Term Debt | 10K | 3.44M | 10K | 0 | 0 | 0 | 0 | 0 | 0 | 673K |
Deferred Revenue (Current) | 108.06K | 1.03M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 131.08K | 335.88K | 6.53M | 120K | 77K | 0 | 883K | 1.81M | 2.27M | 2.8M |
Current Ratio | 2.78x | 0.32x | 1.45x | 3.26x | 21.34x | 61.78x | 20.18x | 13.39x | 14.37x | 15.84x |
Quick Ratio | 2.78x | 0.32x | 1.45x | 3.26x | 21.34x | 61.78x | 20.18x | 13.39x | 14.37x | 15.84x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 329.62K | 215.62K | 2.12M | 374K | 14.54M | 487K | 2.35M | 2.13M | 1.45M | 921K |
Long-Term Debt | 0 | 0 | 0 | 0 | 13.97M | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 165K | 187K | 80K | 1.94M | 1.66M | 983K | 2.84M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 329.62K | 215.62K | 2.12M | 209K | 387K | 407K | 412K | 468K | 468K | 483K |
Total Liabilities | 2.1M | 6.46M | 10.5M | 3.6M | 16.51M | 2.95M | 7.55M | 11.73M | 13.36M | 8.63M |
Total Debt | 10K | 3.43M | 10K | 410K | 14.42M | 188K | 2.48M | 2.23M | 1.61M | 1.11M |
Net Debt | -4.48M | 1.79M | -11.56M | -9.54M | -26.63M | -150.22M | -13.56M | -68.17M | -92.49M | -10.13M |
Debt / Equity | 0.00x | - | 0.01x | 0.06x | 0.55x | 0.00x | 0.02x | 0.02x | 0.01x | 0.01x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.01x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.12x |
Interest Coverage | -12711.94x | -42.33x | -5.14x | - | -54.74x | -21.72x | - | - | - | - |
Total Equity | 8.53M▲ 0% | -3.96M▼ 146.4% | 1.75M▲ 144.2% | 7.37M▲ 320.4% | 26.1M▲ 254.4% | 149.47M▲ 472.7% | 116.17M▼ 22.3% | 121M▲ 4.2% | 162.13M▲ 34.0% | 116.83M▲ 0% |
Equity Growth % | -2.79% | -146.44% | 144.23% | 320.38% | 254.37% | 472.71% | -22.28% | 4.16% | 33.99% | 133.74% |
Book Value per Share | 10.33 | -3.56 | 0.99 | 1.28 | 3.40 | 7.67 | 2.27 | 2.35 | 2.13 | 1.12 |
Total Shareholders' Equity | 8.53M | -3.96M | 1.75M | 7.37M | 26.1M | 149.47M | 116.17M | 121M | 162.13M | 116.83M |
Common Stock | 49.23K | 62.17K | 4K | 6K | 8K | 34K | 37K | 53K | 87K | 96K |
Retained Earnings | -64.32M | -94.18M | -126.9M | -147.24M | -168.14M | -209.2M | -260.99M | -329.44M | -403.86M | -460.95M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -1.99M | -517.79K | 0 | 0 | 0 | 0 | -351K | -79K | -7K | -115K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RZLT Cash Flow Statement
Rezolute, Inc. (RZLT) cash flow — operating, investing & free cash flow history
| Metric | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -13.31M | -14.11M | -15.3M | -24.17M | -20.44M | -39.62M | -44.48M | -57.37M | -69.08M | -73.48M |
Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | -26.91% | -6.02% | -8.44% | -57.92% | 15.42% | -93.81% | -12.28% | -28.97% | -20.41% | -55.25% |
Net Income | -20.28M | -29.86M | -30.45M | -20.33M | -20.9M | -41.06M | -51.79M | -68.46M | -74.41M | -81.48M |
Depreciation & Amortization | 1.11M | 1.07M | 49K | 18K | 13K | 13K | 30K | 36K | 31K | 31K |
Stock-Based Compensation | 6.01M | 5.1M | 2.64M | 3.32M | 3.96M | 3.69M | 7.27M | 7.36M | 7.12M | 8.31M |
Deferred Taxes | 0 | 2.93M | -17K | 102K | -1.78M | 0 | -1.36M | 0 | 0 | 0 |
Other Non-Cash Items | 1.2K | 5.63M | 4.12M | 222K | 384K | -1.61M | 352K | 595K | -1.86M | 2.66M |
Working Capital Changes | -155.36K | 1.03M | 8.36M | -7.49M | -2.12M | -642K | 1.02M | 3.1M | 47K | -3M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 112.35K | 824.45K | -548K | 330K | 142K | -11K | 2.14M | 1.08M | 1.42M | -3.31M |
Cash from Investing | -195.38K | 1.73M | 231K | 0 | 0 | 0 | -101.46M | 48.7M | -14.54M | -33.05M |
Capital Expenditures | -407.93K | -5.82K | -47K | 0 | 0 | 0 | -153K | 0 | 0 | 0 |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 1.55M | 278K | 0 | 0 | 0 | 101.46M | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 212.55K | 1.74M | 278 | 0 | 0 | 0 | -101.46M | 0 | 0 | 68.49M |
Cash from Financing | 13.93M | 9.54M | 25M | 22.55M | 51.53M | 148.98M | 11.57M | 63.03M | 107.33M | 103.17M |
Debt Issued (Net) | -23.13K | 5.34M | 0 | 0 | 15M | -16.01M | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 14.64M | 4.5M | 25M | 24.05M | 41M | 133.6M | 12.33M | 49.02M | 107.33M | 82.42M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -683.19K | -299.27K | 0 | -1.5M | -4.47M | 31.39M | -759K | 14.01M | 0 | 20.76M |
Net Change in Cash | 424.52K▲ 0% | -2.84M▼ 769.1% | 9.93M▲ 449.5% | -1.62M▼ 116.3% | 31.09M▲ 2021.6% | 109.36M▲ 251.7% | -134.37M▼ 222.9% | 54.36M▲ 140.5% | 23.71M▼ 56.4% | -3.36M▲ 0% |
Free Cash Flow | -13.72M▲ 0% | -14.12M▼ 2.9% | -15.35M▼ 8.7% | -24.17M▼ 57.4% | -20.44M▲ 15.4% | -39.62M▼ 93.8% | -44.63M▼ 12.7% | -57.37M▼ 28.5% | -69.08M▼ 20.4% | -73.48M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | - | - |
FCF Growth % | -9.05% | -2.91% | -8.73% | -57.44% | 15.42% | -93.81% | -12.67% | -28.53% | -20.41% | -12.01% |
FCF per Share | -16.61 | -12.68 | -8.64 | -4.20 | -2.66 | -2.03 | -0.87 | -1.11 | -0.91 | -0.71 |
FCF Conversion (FCF/Net Income) | 0.66x | 0.47x | 0.50x | 1.19x | 0.98x | 0.96x | 0.86x | 0.84x | 0.93x | 0.90x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RZLT Key Ratios
Rezolute, Inc. (RZLT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -234.41% | -1307.66% | -1736.13% | -446.05% | -124.92% | -46.77% | -38.99% | -57.73% | -52.56% | -58.82% |
Return on Invested Capital (ROIC) | -344.65% | -2293.34% | - | - | - | - | -82.45% | -67.95% | -97.85% | -60.42% |
Debt / Equity | 0.00x | - | 0.01x | 0.06x | 0.55x | 0.00x | 0.02x | 0.02x | 0.01x | 0.01x |
Interest Coverage | -12711.94x | -42.33x | -5.14x | - | -54.74x | -21.72x | - | - | - | - |
FCF Conversion | 0.66x | 0.47x | 0.50x | 1.19x | 0.98x | 0.96x | 0.86x | 0.84x | 0.93x | 0.90x |
Related:RZLT Dividend History·RZLT Revenue History·RZLT Price History·RZLT P/E History·RZLT Financial Ratios·RZLT Institutional Holders
RZLT SEC Filings & Documents
Rezolute, Inc. (RZLT) SEC filings — annual & quarterly reports (10-K, 10-Q)
RZLT Frequently Asked Questions
Rezolute, Inc. (RZLT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Rezolute, Inc. (RZLT) grew revenue by 0.0% over the past year. Growth has been modest.
Rezolute, Inc. (RZLT) reported a net loss of $81.5M for fiscal year 2025.
Dividend & Returns
Rezolute, Inc. (RZLT) has a return on equity (ROE) of -52.6%. Negative ROE indicates the company is unprofitable.
Rezolute, Inc. (RZLT) had negative free cash flow of $73.5M in fiscal year 2025, likely due to heavy capital investments.